Evotec's new UK ADMET purchase Cyprotex completes integration move
The acquisition of Cyprotex plc by German CRO Evotec AG was announced in December in a £55m buyout. Along with a change in name to Cyprotex, plans were also set in motion to relocate the firm’s UK assets in Macclesfield to a site down the road in the Alderley Park BioHub.
This was “for consolidation of Cyprotex’ UK operations into a single facility”, explained Mario Polywva, Evotec AG’s COO.
Cyprotex’ business is based on a high quality in vitro ADMET platform. This comprises of mechanistic toxicology and high content toxicology screening services, including its proprietary Cloe PK predictive modelling and Cell Ciphr toxicity screening technologies.
The Alderley Park site in Northwest England covers around 2300 sq metres of office and laboratory space, and will accommodate all 106 of Cyprotex’ UK staff.
“This is an important step in the integration of Cyprotex into the Evotec Group," added Polywva.
"Moving to Alderley Park allows for the expansion [of the firm’s] operations into a first-class scientific facility, which of course will serve to benefit our client base.”
Cyrprotex also has US operations in Michigan and Massachusetts.
